Hearing loss company Acousia Therapeutics: first patient with age-related hearing loss treated with ACOU085

"This next step of Acousia's otoprotective drug candidate ACOU085 into studies on patients suffering from presbycusis marks an important milestone on our path towards making hearing loss a treatable disease," says Dr. Tim Boelke, Chief Executive Officer and Chief Medical Officer of the company. "This next step of Acousia's otoprotective drug candidate ACOU085 into studies on patients suffering from presbycusis marks an important milestone on our path towards making hearing loss a treatable...

"This next step of Acousia's otoprotective drug candidate ACOU085 into studies on patients suffering from presbycusis marks an important milestone on our path towards making hearing loss a treatable disease," says Dr. Tim Boelke, Chief Executive Officer and Chief Medical Officer of the company.

"I am extremely proud that our hypothesis-driven, scientific work is now moving into the clinical stage only 6 years after initiating a full-fledged de novo drug development program on a novel, highly innovative drug target," adds Hubert Löwenheim, Professor and Chair of the Department of Otolaryngology-Head & Neck Surgery of the University of Tübingen and Acousia Therapeutics co-founder.

About Acousia Therapeutics GmbH

Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration.

Contact

Tim Boelke, M.D.
[email protected]
www.acousia.com

+49-7071-298 818 6